Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04044937 · ClinicalTrials.gov registry record · Phase 2
Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
A Phase 2 study, sponsored by Thomas Hope.
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT04044937 is a Phase 2 study that has completed, run by Thomas Hope. The registered enrollment target is 143 participants.
The verdict
NCT04044937, a Phase 2 study, has completed, sponsored by Thomas Hope.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize the grade of glial neoplasms. Imaging agents such as FET can help oncologist to see the tumor better during a positron emission tomography (PET) scan.
Interventions
- PROCEDURE Positron Emission Tomography (PET)
- DRUG F-18 Fluoroethyltyrosine (FET)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04044937
The ClinicalTrials.gov registry entry for NCT04044937 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Hope, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Positron Emission Tomography (PET) is the first listed.
NCT04044937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04044937 about?
NCT04044937 is a clinical study titled "Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms". This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize th...
What is the current status of trial NCT04044937?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2018-10-29. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT04044937?
The interventions under investigation include: Positron Emission Tomography (PET) (PROCEDURE), F-18 Fluoroethyltyrosine (FET) (DRUG).
Who is sponsoring clinical trial NCT04044937?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.